Gotoh Masahiro, Ichikawa Hitoshi, Arai Eri, Chiku Suenori, Sakamoto Hiromi, Fujimoto Hiroyuki, Hiramoto Masaki, Nammo Takao, Yasuda Kazuki, Yoshida Teruhiko, Kanai Yae
Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
Genes Chromosomes Cancer. 2014 Dec;53(12):1018-32. doi: 10.1002/gcc.22211. Epub 2014 Sep 18.
The aim of this study was to clarify the participation of expression of chimeric transcripts in renal carcinogenesis. Whole transcriptome analysis (RNA sequencing) and exploration of candidate chimeric transcripts using the deFuse program were performed on 68 specimens of cancerous tissue (T) and 11 specimens of non-cancerous renal cortex tissue (N) obtained from 68 patients with clear cell renal cell carcinomas (RCCs) in an initial cohort. As positive controls, two RCCs associated with Xp11.2 translocation were analyzed. After verification by reverse transcription (RT)-PCR and Sanger sequencing, 26 novel chimeric transcripts were identified in 17 (25%) of the 68 clear cell RCCs. Genomic breakpoints were determined in five of the chimeric transcripts. Quantitative RT-PCR analysis revealed that the mRNA expression levels for the MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, MINPP1, TEX264, FAM107A, UPF3A, CDC16, MCCC1, CPSF3, and ASAP2 genes, being partner genes involved in the chimeric transcripts in the initial cohort, were significantly reduced in 26 T samples relative to the corresponding 26 N samples in the second cohort. Moreover, the mRNA expression levels for the above partner genes in T samples were significantly correlated with tumor aggressiveness and poorer patient outcome, indicating that reduced expression of these genes may participate in malignant progression of RCCs. As is the case when their levels of expression are reduced, these partner genes also may not fully function when involved in chimeric transcripts. These data suggest that generation of chimeric transcripts may participate in renal carcinogenesis by inducing dysfunction of tumor-related genes.
本研究的目的是阐明嵌合转录本的表达在肾癌发生中的作用。对来自68例透明细胞肾细胞癌(RCC)患者的68份癌组织标本(T)和11份非癌肾皮质组织标本(N)进行了全转录组分析(RNA测序),并使用deFuse程序探索候选嵌合转录本。作为阳性对照,分析了两例与Xp11.2易位相关的RCC。经逆转录(RT)-PCR和桑格测序验证后,在68例透明细胞RCC中的17例(25%)中鉴定出26种新的嵌合转录本。确定了其中5种嵌合转录本的基因组断点。定量RT-PCR分析显示,在初始队列中参与嵌合转录本的伙伴基因MMACHC、PTER、EPC2、ATXN7、FHIT、KIFAP3、CPEB1、MINPP1、TEX264、FAM107A、UPF3A、CDC16、MCCC1、CPSF3和ASAP2的mRNA表达水平,在第二队列的26份T样本中相对于相应的26份N样本显著降低。此外,T样本中上述伙伴基因的mRNA表达水平与肿瘤侵袭性和患者较差的预后显著相关,表明这些基因表达的降低可能参与了RCC的恶性进展。正如它们的表达水平降低时的情况一样,这些伙伴基因在参与嵌合转录本时也可能无法充分发挥功能。这些数据表明,嵌合转录本的产生可能通过诱导肿瘤相关基因的功能障碍参与肾癌的发生。